Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2024.12.007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Jessica Lucchetti und 23 weiteren Autor:innen. Beteiligte Einrichtung: Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Recombinant Fusion Proteins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Both aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy for this setting.
Methods
We launched a multicenter, retrospective, observational study to assess and compare clinical efficacy of aflibercept-based and bevacizumab-based regimens as II-line treatment for patients with mCRC. Patients with KRAS/NRAS/BRAF -wild type and KRAS/NRAS mutant tumors were also analyzed separately.
Findings
348 consecutive patients were included, of whom 153 and 195 were treated with bevacizumab- and aflibercept-based regimens, respectively. The median age of the study population was 64 years, with 54.6% of males, 31.6% with ECOG-PS ≥1, and 62.9% with left-sided primary tumors. Overall, 81.9% underwent prior primary tumor resection, 61.5% had ≥2 metastatic sites and 30.7% had peritoneal disease. Patients treated with aflibercept showed an increased risk of death (corrected [co]-HR 1.92, 95%CI: 1.37-2.68), of disease progression/death (co-HR 1.43, 95%CI: 1.12-1.82) and a decreased objective response rate (ORR) (21.5% vs 34.7%, p=0.007) in comparison to bevacizumab. Of note, patients treated with II-line bevacizumab were more frequently treated in the third line setting after disease progression (91.1% vs 68.5%). Among the 242 patients included in the KRAS/NRAS mutant cohort, treatment with bevacizumab was associated with longer overall survival (OS) (18.0 months vs 12.5 months, p=0.0069), but similar progression free survival (PFS) (p=0.32) and ORR (p=0.57). Among the 80 patients included in the KRAS/NRAS, BRAF wild type cohort, patients treated with bevacizumab achieved significantly longer OS (20.2 months vs 10.6 months, p=0.013), PFS (8.4 months vs 3.7 months, p=0.0002), and higher ORR (48.6% vs 15.0%, p=0.0016), compared to those treated with aflibercept. All the results were independently confirmed with inverse probability of treatment weighting and with fixed multivariable Cox regressions.
Conclusion
These findings seem to support the use of bevacizumab-based over aflibercept-based regimens as II-line treatment of patients with mCRC, especially in those with KRAS/NRAS and BRAF wild type tumors. Micro abstract Aflibercept- and bevacizumab-based regimens are two valuable second-line (II-line) treatment options for metastatic colorectal cancer (mCRC). However, no head-to-head trials have compared these anti-angiogenic strategies in this setting. This multicenter, retrospective, observational study assessed the clinical efficacy of these regimens. A total of 348 patients were included: 153 treated with bevacizumab-based regimens and 195 treated with aflibercept-based regimens. The findings support the use of bevacizumab-based regimens, particularly in patients with RAS/BRAF wild-type tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy. Electronic address…
- Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
- Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
- Unità Operativa Complessa Oncologia, Ospedale Santa Maria Goretti, Latina, Italy.
Zitieren
APA
Lucchetti, J., Angotti, L., Parisi, A., Basso, M., Polito, M. G., Zoratto, F., Di Giacomo, E., Nitti, D., Minelli, A., Salvatore, L., Calegari, M. A., Lo Prinzi, F., Gemma, D., Signorelli, C., Veroli, M., Anghelone, A., Galbato Muscio, L., Di Cocco, B., Trombetta, G., …, & Tonini, G. (2025). Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.12.007
Vancouver
Lucchetti J, Angotti L, Parisi A, Basso M, Polito MG, Zoratto F, et al. Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.12.007
BibTeX
@article{Lucchetti2025,
author = {Lucchetti, Jessica and Angotti, Lorenzo and Parisi, Alessandro and Basso, Michele and Polito, Mariam Grazia and Zoratto, Federica and Di Giacomo, Emanuela and Nitti, Daniele and Minelli, Alessandro and Salvatore, Lisa and Calegari, Maria Alessandra and Lo Prinzi, Federica and Gemma, Donatello and Signorelli, Carlo and Veroli, Margherita and Anghelone, Annunziato and Galbato Muscio, Luca and Di Cocco, Barbara and Trombetta, Giorgio and Morelli, Cristina and Schietroma, Francesco and Vincenzi, Bruno and Cortellini, Alessio and Tonini, Giuseppe},
title = {Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2024.12.007}
}
EUVIMED